Series C · Biotech · Zurich, Switzerland · Founded 2017 · 50–50 employees
CUTISS is a late-stage clinical TechBio company developing denovoSkin, a personalized bio-engineered skin graft for burns and skin defects, with Phase III trials underway in Europe and over 60 patients treated. Founded in 2017 as a University of Zurich spin-off, it features a patented automation platform for scalable production and has Orphan Drug Designation from EMA, FDA, and Swissmedic. In 2025, it closed a Series C round with new strategic investors including Rode Kruis Ziekenhuis for European expansion.
No open roles listed right now.